Hafiz Rashid Hussain

Dr. Hafiz Rashid Hussain


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
HHHafiz Rashid Hussain
Hafiz Rashid Hussain
SBSajid Bashir
Sajid Bashir
Asif MahmoodAsif Mahmood
Asif Mahmood
RSRai Muhammad Sarfraz
Rai Muhammad Sarfraz
MKMisbah Kanwal
Misbah Kanwal
INImran Nazir
Imran Nazir

3 March 2025 in Journal of Drug Targeting
Verified
Journal Article
Closed access
MRMuneeb Ur Rahman
Muneeb Ur Rahman
HHHafiz Rashid Hussain
Hafiz Rashid Hussain
HAHabiba Akram
Habiba Akram
Muhammad SarfrazMuhammad Sarfraz
Muhammad Sarfraz
MNMuhammad Nouman
Muhammad Nouman
MIMemona Ishtiaq
Memona Ishtiaq
Breast cancer remains one of the significant health issues across the globe, being diagnosed in millions of women worldwide annually. Conventional therapeutic options have substantial adverse effects due to their non-specificity and limited drug bioavailability. Niosomes, being novel drug delivery systems formed from non-ionic surfactants, with or without cholesterol and charge-inducing agents, are used as therapeutic options in treating BC. Their formulation by various methods enhances the therapeutic efficacy and bioavailability and minimizes side effects. Niosomal formulation of tamoxifen exhibits target drug delivery with enhanced stability, whereas docetaxel and methotrexate show sustained and controlled drug release, respectively.5-Fluorouracil, doxorubicin, paclitaxel, cyclophosphamide, and epirubicin show improved cytotoxic effects against BC when combined with other agents. Furthermore, repurposed niosomal formulations of anti-cancer drugs show improved penetration, reduced tumor volume, and significantly enhanced anti-tumor effect. This review article focuses on the composition of niosomes and their application in BC treatment and then examines how niosomes could contribute to BC research.

5 April 2025 in Prospects in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
MRMuneeb Ur Rahman
Muneeb Ur Rahman
HHHafiz Rashid Hussain
Hafiz Rashid Hussain
HAHabiba Akram
Habiba Akram
FGFaisal Gulzar
Faisal Gulzar
MNMuhammad Nouman
Muhammad Nouman
ZKZaha Kalsoom
Zaha Kalsoom
Nifedipine (NIFE) is a potent first-generation dihydropyridine calcium channel antagonist that belongs to the BCS-II drug. It inhibits calcium entry through L-type channels and disrupts the Ca-calmodulin complex, which ultimately blocks myosin light chain kinase activation, resulting in vasodilation, reduction in blood pressure, and negative chronotropic effect, thus slowing the heart rate. NIFE was used in the treatment of hypertension and angina. However, physicochemical properties, pharmacokinetic profile, mechanism of action, and therapeutic efficacy explain the widespread use of medication in various medical conditions. With a primary focus on its calcium channel-blocking properties, NIFE has demonstrated therapeutic efficacy in addressing classical vasospastic disorders, such as Raynaud's phenomenon, by modulating vascular function and reducing the episodes of digital ischemia. NIFE has been proven beneficial in ureteral stones by increasing their passage rates and in migraine by producing vasodilation. NIFE exhibits therapeutic effects by inhibiting proliferation and metastasis in colorectal cancer through reactivating tumour immunity. Similarly, it has great potential in obstetrics, as it effectively manages preterm labor by delaying the delivery and optimizing fetal conditions. Moreover, its applications can expand into evolving domains, such as achalasia, glaucoma, and chilblains, and potentially as an effective intervention against COVID-19.

28 April 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
HHHafiz Rashid Hussain
Hafiz Rashid Hussain
Nabeel AhmedNabeel Ahmed
Nabeel Ahmed
MAMuhammad Waseem Akram
Muhammad Waseem Akram
FGFaisal Gulzar
Faisal Gulzar
JKJawad Akbar Khan
Jawad Akbar Khan
MRMuneeb Ur Rahman
Muneeb Ur Rahman
Introduction: Every one in seven people with Type-I or Type-II diabetes suffers from fear of hypoglycemia (FOH). Its impact on quality of life, glycemic control, and health outcomes is well studied. However, its relationship with sleep quality remains underexplored, particularly in developing societies. We hypothesize that FOH is a key predictor of sleep quality in Type-I and Type-II patients with diabetes and, therefore, needs detailed investigation.Methods: A multicentric study was conducted across five cities and six centers of Punjab. Data from 310 diabetes patients were analyzed using the Hypoglycemia Fear Survey-II (HFS-II) Scale and the Pittsburgh Sleep Quality Index (PSQI). Statistical analyses explored subgroup variations, correlations, regression models, and receiver operator curve (ROC) estimation.Results: The study reports 57.70% of patients with poor sleep among whom 47% had elevated FOH. Sleep quality, age, gender, diabetes duration, and insulin route significantly correlated with FOH (p < 0.05), while glycemic control and insulin use did not. Binary logistics regression showed that for every one-unit increase in FOH, the odds of experiencing poor sleep increased by approximately 3.7% (p < 0.001; OR 1.037). Five out of seven sleep components (sleep quality, efficiency, disturbance, medication use, and daytime dysfunction) were significantly related to FOH. We hypothesize that FOH might specifically influence the quality rather than the initiation or termination of the sleep cycle. ROC analysis revealed that HFS-II may be better at diagnosing poor sleep in patients than by chance (p < 0.001) with an AUC of 0.691.Conclusion: FOH is a key predictor of sleep quality among patients with diabetes. Healthcare providers should prioritize patient education targeting common FOH concerns and assess patients with disturbed sleep for elevated FOH levels, as it may contribute to sleep disturbances.

13 November 2024 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
MMMuhammad Abid Mustafa
Muhammad Abid Mustafa
HHHafiz Rashid Hussain
Hafiz Rashid Hussain
JKJawad Akbar Khan
Jawad Akbar Khan
NANadeem Ahmad
Nadeem Ahmad
SBSajid Bashir
Sajid Bashir
INImran Nazir
Imran Nazir

1 July 2025
Verified
Journal Article
Open access
MRMuneeb Ur Rahman
Muneeb Ur Rahman
HHHafiz Rashid Hussain
Hafiz Rashid Hussain
SMSumaira Malik
Sumaira Malik
SRSana Razzaqe
Sana Razzaqe
UAUsama Athar
Usama Athar
WIWajeeha Ismail
Wajeeha Ismail
The utilization of e-cigarettes among youth in Pakistan is increasing due to their attractive appearance, user-friendly design, reduced smoking discomfort, and availability in a variety of flavors. Although e-cigarettes are often perceived as less toxic than traditional cigarettes, they still pose significant health risks such as respiratory issues, cardiovascular problems, potential neurodevelopmental effects in adolescents, and increased likelihood of transitioning to conventional tobacco products due to the presence of harmful chemicals and ingredients such as nicotine and other toxic substances. Adolescents in Pakistan have strong opinions about e-cigarette use, primarily influenced by sociocultural values; Westernization and globalization have made vaping appear to be a chic and sophisticated lifestyle choice. Moreover, views on addiction, dependency, and substance use are shaped by social backgrounds, religious beliefs, and cultural norms. Aggressive marketing techniques are employed by e-cigarette manufacturers, mainly targeting tech-savvy youth through digital platforms and social media influencers, which have also contributed to the rapid rise in e-cigarette use among young people in Pakistan. The current study underscores the necessity for culturally compatible interventions and policies, including educational programs, stringent regulations to limit access for young people, and comprehensive public health campaigns that counteract the influence of marketing by e-cigarette manufacturers. Additionally, healthcare providers should be trained to offer culturally sensitive cessation programs that support adolescents in quitting e-cigarettes and provide resources to mitigate the health hazards associated with e-cigarette use, including nicotine addiction and other adverse health effects, and to promote tobacco cessation in Pakistan.